Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany.
Jordi CastellsagueBeatriz Poblador-PlouMaria Giner-SorianoMarie LinderOliver ScholleBrian CalingaertChristine BuiAlejandro AranaClara LagunaFrancisca Gonzalez-RubioAlbert Roso-LlorachAlexandra Prados-TorresSusanna Perez-GutthannPublished in: Pharmacoepidemiology and drug safety (2018)
This study indicates that the risk minimization measures implemented by the EMA for the use of cilostazol have been effective in all European countries studied, except for smoking cessation before initiating cilostazol, which remains an area of improvement.